Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries (Teva) has reported the availability of new resources to support the recently introduced Tjet injector system. Its a needle-free device designed to deliver the company's Tev-Tropin [somatropin (rDNA origin) for injection] brand human growth hormone (hGH) to children, who have growth failure due to inadequate secretion of normal endogenous growth hormone.
Subscribe to our email newsletter
The company claims that Tjet uses a needle-free delivery system that releases the same amount of Tev-Tropin as a traditional syringe in two seconds.
Tjet works by releasing a thin stream of Tev-Tropinthat penetrates the stratum corneum (outermost layer skin) and is delivered into the subcutaneous (below the skin) tissue in two seconds, through a tiny opening in the skin less than one third the size of a 30-gauge needle. With flexible dosing in increments of 0.05mg, Tjet delivers the prescribed dose of Tev-Tropin with one click of a button.
The company said that Tjet can be used on the back of the upper arm, the upper outer thigh, stomach, or buttocks. It has an eco-friendly design that means less waste compared to needle-pen devices or traditional syringe administration.
Teva is likely to provide Tjet and replacement supplies free of charge with all prescriptions for Tev-Tropin, when requested by a physician.